Haemophilus parainfluenzae


Also found in: Encyclopedia, Wikipedia.

Hae·moph·i·lus par·a·in·flu·en·'zae

a bacterial species that is usually nonpathogenic but occasionally causes subacute endocarditis.

Hae·moph·i·lus par·a·in·flu·enzae

(hē-mofi-lŭs pară-inflū-enzē)
A bacterial species that has been associated with human infection, including cases of endocarditis

Haemophilus parainfluenzae

A species that normally colonizes the human respiratory tract and sometimes causes serious infections, including abscesses, endocarditis, and sepsis.
See also: Haemophilus

Haemophilus

a genus of hemophilic gram-negative coccobacilli or rod-shaped bacteria.

Haemophilus agni
see H. somnus now called Histophilussomni.
Haemophilus avium
now called Avibacteriumavium.
Haemophilus bovis
see moraxellabovis.
Haemophilus equigenitalis
see taylorella equigenitalis.
Haemophilus gallinarum
now classified as Avibacteriumparagallinarum.
Haemophilus haemoglobinophilus
found on canine genitalia; sometimes linked to puppy mortality but not often a cause of disease.
Haemophilus influenzaemurium
the cause of respiratory disease and conjunctivitis in mice.
Haemophilus ovis
now called Histophilus somni.
Haemophilus paracuniculus
may be associated with mucoid enteropathy in rabbits.
Haemophilus paragallinarum
now called Avibacteriumparagallinarum.
Haemophilus parahemolyticus (syn. Haemophilus pleuropneumoniae)
see actinobacilluspleuropneumoniae.
Haemophilus parainfluenzae
reputed to cause a syndrome in pigs similar to Glasser's disease (H. suis, H. parasuis).
Haemophilus parasuis
a common concurrent infection with swine influenza virus and causes glasser's disease of swine.
Haemophilus piscium
a cause of ulceration of the gills and mouth of trout.
Haemophilus somnus
now called Histophilus somni.
Haemophilus suis
now classified as H. parasuis (above).
References in periodicals archive ?
Abscess fluid cultures from drainage revealed Prevotella intermedia, Haemophilus parainfluenzae and Streptococcus spp.
Infectious causes of acute COPD exacerbations Bacteria Viruses Non-typeable Haemophilus influenzae Rhinovirus Moraxella catarrhalis Influenza Streptococcus pneumoniae Parainfluenza Pseudomonas aeruginosa Coronavirus Enterobacteriaceae Adenovirus Haemophilus parainfluenzae Respiratory syncitial virus 'Atypical bacteria' Human metapneumovirus
With this approval, the in vitro profile of TYGACIL has now been expanded to include: Haemophilus influenzae (ampicillin-resistant) and Haemophilus parainfluenzae.
Haemophilus parainfluenzae is a gram-negative bacterium that is a normal habitant and an opportunistic pathogen of the respiratory tract.
The most common infecting organisms were Haemophilus parainfluenzae (n = 30), followed by Staphylococcus aureus, S.
FACTIVE is also approved for the five-day treatment of AECB due to Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis.
In 2004, FACTIVE was approved in Canada for the treatment of AECB caused by Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis and Staphylococcus aureus.
This five-day, 750 mg once-daily dosing regimen of LEVAQUIN is also approved in adults for community-acquired pneumonia due to penicillin- susceptible Streptococcus pneumoniae (excluding multi-drug-resistant strains*), Haemophilus influenzae, Haemophilus parainfluenzae, Chlamydia pneumoniae, or Mycoplasma pneumoniae.
FACTIVE is approved for the five-day treatment of AECB caused by Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae or Moraxella catarrhalis and for the seven-day treatment of mild to moderate CAP caused by Streptococcus pneumoniae (including multi-drug resistant strains), Haemophilus influenzae, Moraxella catarrhalis, Mycoplasma pneumoniae, Chlamydia pneumoniae or Klebsiella pneumoniae.
FACTIVE tablets are approved in Canada for treating acute bacterial exacerbations of chronic bronchitis caused by Streptococcus pneumonia, Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis and Staphylococcus aureus.
Avelox is approved to treat: Acute Bacterial Exacerbations of Chronic Bronchitis (ABECB) caused by Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Staphylococcus aureus, or Moraxella catarrhalis; Acute Bacterial Sinusitis (ABS) caused by Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis; Community Acquired Pneumonia (CAP) caused by Streptococcus pneumoniae (including multi-drug resistant strains*), Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, Klebsiella pneumoniae, Mycoplasma pneumoniae, or Chlamydia pneumoniae; and Uncomplicated Skin and Skin Structure Infections (uSSSI) caused by Staphylococcus aureus or Streptococcus pyogenes.
LEVAQUIN is indicated to treat mild-to-severe community acquired pneumonia (CAP) due to Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydia pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae.

Full browser ?